We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $20B
1-Year Est. Return 154.41%
This Fund
S&P 500
This Quarter Est. Return
+1.74%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$7.1B
AUM Growth
+$59.7M
Cap. Flow
-$1.53B
Cap. Flow %
-21.52%
Top 10 Hldgs %
75.68%
Holding
101
New
15
Increased
16
Reduced
17
Closed
6

Top Buys

Rank Stock Value
1
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$78.6M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$57.7M
3
ANAC
ANACOR PHARMACEUTICALS INC COM
ANAC
+$22.5M
4
DYAX
DYAX CORPORATION
DYAX
+$15.4M
5
QCOR
QUESTCOR PHARMA INC
QCOR
+$13.6M

Top Sells

Rank Stock Value
1
VPHM
VIROPHARMA INC
VPHM
+$220M
2
GILD icon
Gilead Sciences
GILD
+$48M
3
PCYC
PHARMACYCLICS INC
PCYC
+$35.3M
4
ARIA
Ariad Pharmaceuticals Inc
ARIA
+$24.5M
5
AEGR
Aegerion Pharmaceuticals
AEGR
+$24.5M

Sector Composition

Rank Sector Weight
1 Healthcare 50.41%
2 Miscellaneous 49.59%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BDSI
51
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$4.98M 0.07%
846,005
– –
AGIO icon
52
Agios Pharmaceuticals
AGIO
$1.98B
$4.93M 0.07%
205,750
+5,750
+3% +$131K
VXRT
53
DELISTED
Vaxart
VXRT
$4.74M 0.07%
+102,738
New +$4.52M
ASMB icon
54
Assembly Biosciences
ASMB
$590M
$4.64M 0.07%
20,264
– –
EPZM
55
DELISTED
Epizyme, Inc
EPZM
$4.58M 0.06%
220,000
+200,000
+1,000% +$5.8M
ABUS icon
56
Arbutus Biopharma
ABUS
$1.02B
$3.98M 0.06%
+500,000
New +$4.16M
GWPH
57
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$3.91M 0.06%
+94,172
New +$2.98M
LGND icon
58
Ligand Pharmaceuticals
LGND
$5.59B
$3.86M 0.05%
117,660
– –
ISEE
59
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$3.33M 0.05%
+103,040
New +$3.06M
ENTA icon
60
Enanta Pharmaceuticals
ENTA
$382M
$2.98M 0.04%
109,097
-15,903
-13% -$385K
RCPT
61
DELISTED
RECEPTOS INC COM STK (DE)
RCPT
$2.9M 0.04%
100,000
– –
MGNX icon
62
MacroGenics
MGNX
$268M
$2.74M 0.04%
+100,000
New +$2.62M
MDGL icon
63
Madrigal Pharmaceuticals
MDGL
$12.5B
$2.62M 0.04%
14,286
– –
PBYI icon
64
Puma Biotechnology
PBYI
$472M
$2.59M 0.04%
25,000
-75,000
-75% -$4.4M
BLUE
65
DELISTED
bluebird bio
BLUE
$2.4M 0.03%
8,836
+227
+3% +$63.4K
UTHR icon
66
United Therapeutics
UTHR
$21.6B
$2.26M 0.03%
20,000
-35,984
-64% -$3.24M
ITMN
67
DELISTED
INTERMUNE INC
ITMN
$2.21M 0.03%
+150,000
New +$2.07M
GERN icon
68
Geron
GERN
$880M
$1.91M 0.03%
425,981
-632,019
-60% -$2.71M
OSUR icon
69
OraSure Technologies
OSUR
$232M
$1.53M 0.02%
243,467
– –
ACHN
70
DELISTED
Achillion Pharmaceuticals
ACHN
$1.51M 0.02%
455,000
– –
RIGL icon
71
Rigel Pharmaceuticals
RIGL
$847M
$1.43M 0.02%
50,000
– –
KPTI icon
72
Karyopharm Therapeutics
KPTI
$36.3M
$1.41M 0.02%
+4,089
New +$1.13M
FOLD
73
DELISTED
Amicus Therapeutics
FOLD
$1.21M 0.02%
515,072
– –
XLRN
74
DELISTED
Acceleron Pharma
XLRN
$1.19M 0.02%
+30,000
New +$724K
TCRT icon
75
Alaunos Therapeutics
TCRT
$3.79M
$1.1M 0.02%
1,695
– –
1 2
3
4

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Baker Bros. Advisors's Q4 2013 Portfolio in Review

As of Q4 2013, Baker Bros. Advisors held 101 positions worth $7.1B, up 0.85% from $7.04B the previous quarter. Its ten largest holdings account for 76% of the portfolio.

Baker Bros. Advisors withdrew a net $1.53B in Q4 2013, closing 6 positions and reducing 17 holdings. Its most notable exit was VIROPHARMA INC, an estimated $220M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 50% of assets, up from 48% a quarter earlier, followed by Miscellaneous.

Against the trend, Baker Bros. Advisors opened a new position in DYAX CORPORATION worth $15.3M.

  • Baker Bros. Advisors's largest Q4 2013 buy was DYAX CORPORATION: 2,026,537 shares worth $15.3M.
  • Baker Bros. Advisors added most to BioMarin Pharmaceuticals in Q4 2013, an estimated $78.6M increase.
  • Baker Bros. Advisors's biggest Q4 2013 reduction was Gilead Sciences, cutting an estimated $48M.
  • Baker Bros. Advisors fully exited VIROPHARMA INC in Q4 2013, selling an estimated $220M.
  • Baker Bros. Advisors's ten largest holdings make up 76% of its $7.1B portfolio in Q4 2013.
  • Baker Bros. Advisors opened 15 new positions and closed 6 in Q4 2013.
  • Baker Bros. Advisors's portfolio value rose 0.85% quarter-over-quarter to $7.1B.

Based on Baker Bros. Advisors's 13F filing for Q4 2013, filed 14 Feb 2014.